title: Calcifediol improves lipid profile in osteopenicatorvastatin-treated postmenopausal women.
abstract: BACKGROUND
  Low vitamin D serum levels have been associated with unfavourable lipid profile and poorer response to atorvastatin. Aims of this study were to test the effects of 25-hydroxyvitamin D3 (calcifediol) compared to parental vitamin D3 (cholecalciferol) supplementation on modifications of plasma 25(OH)D levels and lipid profile.
  
  
  METHODS
  Fifty-seven postmenopausal women (aged 59.03 ± 6.73 years) who were at low risk of fracture and with basal plasma 25(OH)D < 30 ng/mL were included if they were on atorvastatin treatment prescribed as appropriate. Recruited women were randomized to receive oral calcifediol or cholecalciferol, both at a dose of 140 μg according to a weekly regimen.
  
  
  RESULTS
  At baseline, 25(OH)D was negatively associated with BMI (r = -0.37; P = 0.004), total cholesterol (r = -0.31; P = 0.01) and LDL-C (r = -0.32; P = 0.02). After 24 weeks, 25(OH)D increased significantly in both groups (P < 0.001), although higher levels were obtained with calcifediol as compared with cholecalciferol (P < 0.001). Only in the calcifediol group, a significant reduction of LDL-C (P = 0.01) and an increase of HDL-C (P = 0.02) were obtained, even after adjustment for age, and baseline BMI, 25(OH)D and lipid levels (P < 0.05). The percentage changes in 25(OH)D levels were associated with the variations of LDL-C (r = -0.44; P = 0.01) and HDL-C levels (r = 0.30; P = 0.10).
  
  
  CONCLUSIONS
  Calcifediol administration in osteopenic and dyslipidemic postmenopausal women with low 25(OH)D improves lipid profile when added to an ongoing atorvastatin treatment.
authors.affiliation: Department of Clinical and Experimental Medicine, University Hospital of Messina, Messina, Italy.
authors.forename: Antonino
authors.initials: A
authors.lastname: Catalano
authors.forename: Nancy
authors.initials: N
authors.lastname: Morabito
authors.forename: Giorgio
authors.initials: G
authors.lastname: Basile
authors.forename: Domenico
authors.initials: D
authors.lastname: Cucinotta
authors.forename: Antonino
authors.initials: A
authors.lastname: Lasco
mesh_terms: D000284:Administration, Oral; D000069059:Atorvastatin; D001851:Bone Diseases, Metabolic / Q000150:complications / Q000188:drug therapy; D002112:Calcifediol / Q000008:administration & dosage*; D002762:Cholecalciferol / Q000008:administration & dosage*; D019587:Dietary Supplements; D004359:Drug Therapy, Combination; D050171:Dyslipidemias / Q000150:complications / Q000188:drug therapy; D005260:Female; D006538:Heptanoic Acids / Q000008:administration & dosage*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D050356:Lipid Metabolism / Q000187:drug effects; D008875:Middle Aged; D017698:Postmenopause / Q000187:drug effects*; D011758:Pyrroles / Q000008:administration & dosage*; D014807:Vitamin D / Q000031:analogs & derivatives / Q000097:blood; D014808:Vitamin D Deficiency / Q000188:drug therapy; D014815:Vitamins / Q000008:administration & dosage*
chemical_list: D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D014815:Vitamins; D014807:Vitamin D; D002762:Cholecalciferol; D000069059:Atorvastatin; C104450:25-hydroxyvitamin D; D002112:Calcifediol
keywords: atorvastatin; calcifediol; lipids; osteopenia; postmenopausal; vitamin D